Your racing horses will help you to quit: A lesson for COPD and α1-antitrypsin deficiency research

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1244-1246

  Soriano, J B ^a,b   Miravitlles, M ^b  

^a Recinte Hospital Joan March   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CARBON MONOXIDE;

AIRWAY OBSTRUCTION; ALPHA ANTITRYPSIN DEFICIENCY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE REGISTRY; DISEASE SEVERITY; EDITORIAL; ENZYME REPLACEMENT; FOLLOW UP; FORCED EXPIRATORY VOLUME; GOLD STANDARD; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LONGITUDINAL STUDY; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG PARENCHYMA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY CONTROL; QUALITY OF LIFE; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SPIROMETRY; SUBSTITUTION THERAPY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; CARBON MONOXIDE; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HORSES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 69249141821     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00026409     Document Type: Editorial

References (23)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
2. Peto R. The horse-racing effect. Lancet 1981; 2: 467-468.
3. 1-antitrypsin deficiency. Eur Respir J 2009; 33: 1335-1341.
4. 1 among patients with severe hereditary α-1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med 1995; 152: 1922-1925.
5. 1-antitrypsin deficiency? Eur Respir J 1997; 10: 2260-2263.
6. 1 decline in individuals with severe deficiency of alpha1-antitrypsin. The α-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49-59.
7. Stolk J, Putter H, Bakker EM, et al. Progression paramenter for emphysema: a clinical investigation. Respir Med 2007; 101: 1924-1930.
8. Osmanliev DP, Joyce H, Watson RA, et al. Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease. Respir Med 2005; 99: 1053-1060.
9. Parr DG, Stoel BC, Stolk J, et al. Validation of computed tomographic lung densitometry for monitoring emphysema in alpha-1-antitrypsin deficiency. Thorax 2006; 61: 485-490.
10. Macintyre N, Crapo RO, Viegi G. Standardization of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735.
11. Stam H, Hrachovina V, Stijnen T, et al. Diffusing capacity dependent on lung volume and age in normal subjects. J Appl Physiol 1994; 76: 2356-2363.
12. Newel Jr JD, Hogg JC, Snider GL. Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur Respir J 2004; 23: 769-775.
13. Bakker ME, Putten H, Stolk J, et al. Assessment of regional progression of pulmonary emphysema with CT densitometry. Chest 2008; 134: 931-937.
14. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with α-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
15. Vidal R, Blanco I, Casas F, et al. Guidelines for the diagnosis and management of α-1-antitrypsin deficiency. Arch Bronconeumol 2006; 42: 645-659.
16. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls and opportunities. Chest 2009 (in press).
17. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
18. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
19. Garcia-Aymerich J, Barreiro E, Farrero E, et al. Patients hospitalised for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000; 16: 1037-1042.
20. Burrows B, Knudson RJ, Camilli AE, et al. The "horse-racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987; 135: 788-793.
21. 1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827.
22. Glymour MM, Weuve J, Berkman LF, et al. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol 2005; 162: 267-278.
23. Derom E, van Weel C, Liistro G, et al. Primary care spirometry. Eur Respir J 2008; 31: 197-203.